The availability of vaccines that contain both measles and rubella components allows for the elimination of both diseases. Although routine infant vaccination with rubella vaccine has had profound effects on the incidence of both acquired and congenital rubella, mass vaccination rapidly stops circulation of the virus and prevents paradoxical increases in susceptibility of women that might result from decreased exposure in childhood. Whereas routine rubella vaccination has eliminated the infection from many developed countries, mass vaccination has rapidly accomplished the same goal in Latin America and the Caribbean, and is being applied in other developing country areas.


Rubella Virus Eastern Mediterranean Region Mass Vaccination Congenital Rubella Syndrome Rubella Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gregg NM (1941) Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 3:35–46Google Scholar
  2. 2.
    Weller TH, Neva FA (1962) Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Bio Med 111:215–225Google Scholar
  3. 3.
    Parkman PD, Beuscher EL, Artenstein MS (1962) Recover of rubella virus from army recruits. Proc Soc Exp Bio Med 111:225–230Google Scholar
  4. 4.
    Cooper LZ (1975) Congenital rubella in the United States. In: Krugman S, Gershon A (eds). Symposium on infections of the fetus and newborn infant. Alan R. Liss, New YorkGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention (1969) Prelicensing statement on rubella virus vaccine: Recommendation of the Public Health Service Advisory committee on Immunization Practices. MMWR 18Google Scholar
  6. 6.
    Tobin JO, Sheppard S, Smithells RW, Milton A, Noach N, Reid D (1985) Rubella in the United Kingdom, 1970–1983. Rev Infect Dis 7:S47–S52PubMedGoogle Scholar
  7. 7.
    Irons B, Lewis MJ, Dahl-Regis M, Castillio-Soloranzo Carrasco P, deQuadro C (2000) Strategies to eradicate rubella in the English-speaking Caribbean. Am J Public Health 90:1545–1549PubMedCrossRefGoogle Scholar
  8. 8.
    Vyse AJ, Gay NJ, White JM, et al. (2002) Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiol Rev 24(2):125–136.PubMedCrossRefGoogle Scholar
  9. 9.
    Castillo-Solorzano C, Carrasco P, Tambini G, et al. (2003) New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas. J Infect Dis 187Suppl 1:S146–152.CrossRefGoogle Scholar
  10. 10.
    de Quadros CA, Izurieta H, Venczel L, Carrasco P (2003) Measles eradication in the Americas: progress to date. J Infect Dis 189Suppl 1:S227–235.Google Scholar
  11. 11.
    Hinman AR, Hersh BS, deQuadros C (1998) Rationale use of Rubella vaccine for the prevention of congenital rubella syndrome in the Americas. Rev Panam Salud Publica 4:156–160PubMedGoogle Scholar
  12. 12.
    World Health Organization (2000) Rubella vaccine: WHO position paper. Wky Epidemiol Rec 75(20):161–166.Google Scholar
  13. 13.
    WHO Weekly Epidemiologic Record (2005) Progress towards elimination of measles and prevention of congenital rubella infection in the WHO European Region 1990–2004. WHO WER 80:66–71Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • S. Reef
    • 1
  1. 1.CDCAtlantaUSA

Personalised recommendations